Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coenzyme Q10 + trimetazidine is a fixed-dose combination of two agents with complementary mechanisms used primarily for cardiovascular protection. - **Coenzyme Q10 (ubiquinone)** is a naturally occurring antioxidant involved in mitochondrial electron transport and cellular energy production. It reduces oxidative stress and supports myocardial function by improving ATP synthesis. - **Trimetazidine** is a metabolic modulator that shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation, thereby enhancing myocardial efficiency under ischemic conditions. It also exhibits antioxidant and anti-inflammatory properties. The combination has demonstrated superior efficacy over monotherapy in reducing markers of inflammation and oxidative stress, improving left ventricular systolic function, and lowering biochemical markers of myocardial damage in acute viral myocarditis[1][2][5]. It has also shown protective effects against drug-induced cardiotoxicity (e.g., cisplatin) by attenuating oxidative stress[3][6]. The primary indications studied include acute viral myocarditis, chronic heart failure, and prevention of cardiotoxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on coenzyme Q10 + trimetazidine.